Drug Profile


Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Roteas; SAVAYSA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Embolism; Stroke; Venous thromboembolism
  • Registered Deep vein thrombosis; Pulmonary embolism
  • No development reported Venous thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Venous-thrombosis(In adolescents, In children, In infants, In neonates) in USA (PO, Suspension)
  • 05 Oct 2017 Daiichi Sankyo plans the SKAF clinical trial for Atrial fibrillation in Japan (UMIN000028754)
  • 15 Sep 2017 Daiichi Sankyo completes a phase IV trial for Venous thromboembolism (prevention, in patients with cancer) in USA, Austria, Hungary, Belgium, France, Italy, Netherlands, Czech Republic, Germany and Spain (NCT02073682)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top